Diabetes & EndocrinologyDPP‑4 inhibitorsSGLT2 inhibitors
Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes
By MedXY|Feb 4, 2026
A new study reveals that combining Empagliflozin with Linagliptin reverses urinary dysbiosis in T2D patients, potentially reducing the risk of urogenital infections and improving treatment adherence compared to SGLT2 inhibitor monotherapy.
